Condition

Relapsed/Refractory B-cell Malignancies clinical trials and research

• 6Clinical trials
• 4Countries

Newest Relapsed/Refractory B-cell Malignancies clinical trials

All recruiting trials (6)

• BAFFR CAR-T therapy for relapsed or treatment-resistant B‑cell cancers

  This study will try BAFFR-directed CAR-T cell therapy in adults whose B‑cell cancers have come back or not responded to prior treatments to see if it is safe and works.

  Recruiting Tongji Hospital · Wuhan · NCT07345728

• IASO208 injection for relapsed or refractory B‑cell lymphomas

  This trial will test IASO208 injections in adults (18–75) whose B‑cell lymphoma has relapsed or not responded to prior standard treatment to see if it is safe and helps control the disease.

  Recruiting Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07309900

• Safety and effectiveness of ZZSW-01 for relapsed or refractory B-cell cancers

  This trial will try injections of ZZSW-01, an extracellular vesicle that delivers CD19 CAR mRNA, in adults with relapsed or refractory CD19‑positive B‑cell cancers to see if it is safe and helps control the disease.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan · NCT07240974

• LVIVO-TaVec100 for relapsed or refractory B-cell malignancies

  This Phase 1 study will test a single dose of LVIVO-TaVec100 to see if it is safe and helps adults with relapsed or refractory B-cell malignancies.

  Recruiting at 5 sites Phase 1 The First Affiliated Hospital with Nanjing Medical University · Hefei, Anhui and 5 other locations · NCT07002112

• Evaluating UBX-303061 for patients with relapsed/refractory B-cell cancers

  This study is testing a new treatment called UBX-303061 to see if it can help people with tough-to-treat B-cell cancers feel better after other treatments have failed.

  Recruiting at 8 sites Phase 1 Ubix Therapeutics, Inc. · Ann Arbor, Michigan and 10 other locations · NCT06590961

• Treatment of relapsed/refractory B-cell cancers with AC676

  This study is testing a new drug called AC676 to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 8 sites Phase 1 Accutar Biotechnology Inc · Denver, Colorado and 8 other locations · NCT05780034

Related topics

Quick answers

How many Relapsed/Refractory B-cell Malignancies clinical trials are recruiting right now?

6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in China (4 trials), United States (2 trials), Poland (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →